Kimberly-Clark to acquire Kenvue in a $48.7 billion deal, sending KVUE shares up 15%. Shareholders to receive $3.50 cash per share, rest in KMB stock. Deal unlocks $2.1 billion in synergies. Stock down 30% from YTD high. Transaction seen as positive with potential for long-term growth and operational upside.

Jim Cramer bullish on KVUE stock post-acquisition, sees significant upside potential. Views Tylenol-related risks as overblown. Shares currently trading at a discount, offering a lucrative 5.1% dividend yield. Wall Street analysts also optimistic, rating KVUE as a “Moderate Buy” with a target price of $19.29, implying a 15% upside.

Read more at Yahoo Finance: Kenvue Stock Pops on News Kimberly-Clark Will Buy It for $48.7B. Is It Too Late to Buy KVUE Here?